Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks

•No case of transfusion-associated variant Creutzfeldt-Jakob disease (vCJD) has been reported since 1999.•Observed and predicted risk estimates of transfusion-acquired vCJD are low.•vCJD-related blood donation criteria no longer seem justified. Secondary transmission of variant Creutzfeldt-Jakob dis...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion medicine reviews 2023-07, Vol.37 (3), p.150747-150747, Article 150747
Main Authors: Pozzo di Borgo, Alexis, Rochette, Samuel, Gaussen, Amaury, O'Brien, Sheila F．, Germain, Marc, Renaud, Christian, Lewin, Antoine
Format: Article
Language:English
Subjects:
Blood Donation
Blood Donors
Blood Transfusion
Creutzfeldt-Jakob Syndrome - epidemiology
Donor deferral
Humans
Leukodepletion
Plasma-derived products
Second wave
Statistical
Transfusion
Transfusion-transmitted infections
United Kingdom - epidemiology
Variant Creutzfeldt-Jakob disease
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•No case of transfusion-associated variant Creutzfeldt-Jakob disease (vCJD) has been reported since 1999.•Observed and predicted risk estimates of transfusion-acquired vCJD are low.•vCJD-related blood donation criteria no longer seem justified. Secondary transmission of variant Creutzfeldt-Jakob disease (vCJD) can occur through blood transfusion or receipt of plasma-derived products. However, published reviews on this topic are outdated, focused on a single country or product type, or did not comprehensively review modeling studies on the risk of transfusion-transmission. We reviewed existing data on observed and modeled risks of transfusion-transmission of vCJD. To date, five patients are suspected to have acquired clinical vCJD or a vCJD infection after receiving a blood or plasma-derived product from a donor who later developed clinical vCJD. All of these cases received a nonleukodepleted blood-derived product in the United Kingdom between 1994 and 1999. Thus, all transfusion-associated cases occurred before the adoption of universal leukodepletion in 1999, which supports the preferential tropism of vCJD for leukocytes. In descriptive cohort studies, no cases of clinical vCJD were observed over ∼13 years of follow-up. In modeling studies, the risk of collecting a contaminated donation was generally
ISSN:0887-7963
1532-9496
DOI:10.1016/j.tmrv.2023.150747